Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 460 (LINC00460)
- Target
- LINC00460
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01
Overview
Long intergenic non-protein coding RNA 460 (LINC00460) is a member of the lincRNA subclass of long non-coding RNAs. It does not encode protein but is implicated in epigenetic and post-transcriptional regulation of gene expression. LINC00460 acts as a miRNA sponge, regulating critical tumor suppressors and oncogenes, thereby influencing cell proliferation, migration, invasion, apoptosis, and therapy resistance in multiple tumor types. Its expression is associated with pathological processes including epithelial-mesenchymal transition and modulation of cancer cell response to chemotherapy agents. Elevated levels of LINC00460 correlate with poor prognosis and increased metastatic potential in several cancers, making it a promising biomarker and potential therapeutic target.
- Other names
- LINC00460HGNC:42809NCBI Gene:728192ENSG00000233532
02
Mechanism of action
Drugs (not specified by name) targeting the axis modulated by LINC00460 may act through inhibition of miRNA sponging, restoring tumor suppressor miRNA function, or epigenetic silencing of LINC00460. Modulation of EGFR-TKI resistance via ceRNA mechanism (by sponging miR-149-5p and affecting IL-6 production).
03
Biological functions
Regulation of cell proliferationRegulation of cell migration and invasionApoptosis modulationActing as a competing endogenous RNA (ceRNA)/miRNA spongeChromatin remodeling and gene expression regulationEMT (epithelial-mesenchymal transition)
04
Disease associations
CancerEsophageal squamous cell carcinomaNasopharyngeal carcinomaBreast cancer (including aggressive subtypes)Lung adenocarcinomaColorectal cancerCervical cancer
05
Safety considerations
Off-target effects for lncRNA-directed therapiesTumor heterogeneity and tissue specificity in LINC00460 action and expression complicates therapeutic targetingUnknown physiological roles of LINC00460 in normal tissues
06
Interacting drugs
Chemotherapeutic agents
3 more in the full profile.
07
Biomarkers
High LINC00460 expression as a biomarker for poor prognosis and aggressive tumor phenotype in various cancers (e.g., breast, esophageal, head-and-neck, lung, colorectal)Potential marker for chemotherapy resistance/response
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 460 (LINC00460).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 460 (LINC00460).